ABBV vs. TEVA: AbbVie vs. Teva Pharmaceutical Stock Comparison

Company Profile

AbbVie (ABBV) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ABBV is classified in Biotechnology while TEVA is classified in Pharmaceuticals.

AbbVie (ABBV) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Teva Pharmaceutical (TEVA) earns 6.65% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

AbbVie (ABBV) at 15.67% retains a top-quartile share of revenue as profit, ahead of Teva Pharmaceutical (TEVA) at 2.94%, which keeps about the industry-typical share.

Both AbbVie (ABBV) at 39.59% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both AbbVie (ABBV) at 8.57% and Teva Pharmaceutical (TEVA) at 4.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: AbbVie (ABBV) reports EPS growth of -0.84%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both AbbVie (ABBV) at 0.87 and Teva Pharmaceutical (TEVA) at 0.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Only one side’s leverage can be read here: Teva Pharmaceutical (TEVA) carries debt-to-equity ratio of 2.13 against its industry range, while AbbVie (ABBV) reports no figure this period.

Financial Strength Metrics

Dividends

Teva Pharmaceutical (TEVA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; Teva Pharmaceutical (TEVA) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both look expensive on trailing earnings: AbbVie (ABBV) at 50.05 sits in the richer P/E ratio quartile, and Teva Pharmaceutical (TEVA) at 99.09 is richer still, above its industry range.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while AbbVie (ABBV) at 7.80 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Teva Pharmaceutical (TEVA) reports 6.23, ranking against industry peers normally.

Valuation Metrics